If you have been reading about Thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Purity determination | Reversed-phase HPLC | UV detection commonly at 214 nm |
| Mass confirmation | Mass spectrometry | Compared against theoretical 888.5 Da |
| Powder storage | -20 C or below | Dry and protected from light |
| Reconstituted storage | Aliquoted and frozen | Avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Sterile water or neutral buffer | Avoid extreme pH conditions |
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
The first humans to form substantial settlements in what is now Knoxville arrived during the Woodland period (c. 1000 B.C. – 1000 A.D). Knoxville's two most prominent prehistoric structures are Late Woodland period burial mounds, one located along Cherokee Boulevard in Sequoyah Hills, and the other located along Joe Johnson Drive on the University of Tennessee campus. Substantial Mississippian period (c. 1100–1600 A.D.) village sites have been found at Post Oak Island (along the river near the Knox-Blount line), and at Bussell Island (near Lenoir City). The Spanish expedition of Hernando de Soto is believed to have traveled down the French Broad Valley and visited the Bussell Island village in 1540 en route to the Mississippi River. A follow-up expedition led by Juan Pardo may have visited village sites in the Little Tennessee Valley in 1567. The records of these two expeditions suggest the area was part of a Muskogean chiefdom known as Chiaha, which was subject to the Coosa chiefdom further to the south. By the 18th century, the Cherokee had become the dominant tribe in the East Tennessee region, although they were consistently at war with the Creeks and Shawnee. The Cherokee people called the Knoxville area kuwanda'talun'yi, which means "Mulberry Place." Most Cherokee habitation in the area was concentrated in the Overhill settlements along the Little Tennessee River, southwest of Knoxville.
== History == The first report of angiogenesis can be traced back to the book A treatise on the blood, inflammation, and gun-shot wounds published in 1794, where Scottish anatomist John Hunter's research findings were compiled. In his study, Hunter observed the growth process of new blood vessels in rabbits. However, he did not coin the term "Angiogenesis," which is now widely used by scholars. Hunter also erroneously attributed the growth process of new blood vessels to the effect of an innate vital principle within the blood. The term "angiogenesis" is believed to have emerged not until the 1900s. The inception of modern angiogenesis research is marked by Judah Folkman's report on the pivotal role of angiogenesis in tumor growth.
==== Variation between animal species ==== Studies on the cell membranes of mammals and reptiles discovered that mammalian cell membranes are composed of a higher proportion of polyunsaturated fatty acids (DHA, omega−3 fatty acid) than reptiles. Studies on bird fatty acid composition have noted similar proportions to mammals but with 1/3rd less omega−3 fatty acids as compared to omega−6 for a given body size. This fatty acid composition results in a more fluid cell membrane but also one that is permeable to various ions (H+ & Na+), resulting in cell membranes that are more costly to maintain. This maintenance cost has been argued to be one of the key causes for the high metabolic rates and concomitant warm-bloodedness of mammals and birds. However polyunsaturation of cell membranes may also occur in response to chronic cold temperatures as well. In fish increasingly cold environments lead to increasingly high cell membrane content of both monounsaturated and polyunsaturated fatty acids, to maintain greater membrane fluidity (and functionality) at the lower temperatures.
Sources: en.wikipedia.org
However, adapted TAILS and COFRADIC workflows have been developed specifically to study the C-termini of proteins. Recently, the Overall Lab tackled another difficulty of C-terminomics, using endopeptidase LysargiNase™ to generate C-termini carrying N-terminal lysine or arginine residues. Previously, C-termini lacked basic residues after endopeptidase digestion and could be missed in LC-MS/MS workflows. Another approach designed at further elucidating protease activity is Proteomic Identification of protease Cleavage Sites (PICS). Beginning with a peptide library generated from endopeptidase digestion of a proteome, this technique allows for screening and characterizing the prime- and non-prime specificity for proteases. After digestion, primary amines and sulfhydryl are chemically blocked before digesting the sample again with the desired protease. Now, protease generated primary amines that constitute the prime site of cleavage can be biotinylated and isolated due to their reactivity and analyzed by LC-MS/MS. Non-prime sides sequences left behind must be determined using bioinformatics analysis of the extracted N-termini and full length protein sequences. These prime and non-prime sites give a full picture of protease cleavage site specificity.
==== 2004 DOE panel ==== In August 2003, the U.S. Secretary of Energy, Spencer Abraham, ordered the DOE to organize a second review of the field. This was thanks to an April 2003 letter sent by MIT's Peter L. Hagelstein, and the publication of many new papers, including the Italian ENEA and other researchers in the 2003 International Cold Fusion Conference, and a two-volume book by U.S. SPAWAR in 2002. Cold fusion researchers were asked to present a review document of all the evidence since the 1989 review. The report was released in 2004. The reviewers were "split approximately evenly" on whether the experiments had produced energy in the form of heat, but "most reviewers, even those who accepted the evidence for excess power production, 'stated that the effects are not repeatable, the magnitude of the effect has not increased in over a decade of work, and that many of the reported experiments were not well documented'". In summary, reviewers found that cold fusion evidence was still not convincing 15 years later, and they did not recommend a federal research program. They only recommended that agencies consider funding individual well-thought studies in specific areas where research "could be helpful in resolving some of the controversies in the field". They summarized its conclusions thus:
==== India ==== Darbar earned ₹18 crore in Tamil Nadu on its first day of release. It grossed ₹135 crore at the domestic box office in the first 11 days of its release. After its theatrical run, in Kerala and Karnataka it collected ₹18–20 crore and ₹35 crore respectively. It earned around ₹30 crore from Andhra Pradesh and Telangana, and around ₹15 crore from the Hindi version.
Sources: en.wikipedia.org
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.
Mass spectrometry is the usual confirmatory method because it measures the intact mass. Reversed-phase chromatography is used alongside it to estimate purity.
Not directly. Reported percentages depend on the chromatographic method, detection wavelength, and integration criteria, so the underlying method details matter.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.